TCR2 Therapeutics Stock Forecast, Price & News

+0.19 (+1.48 %)
(As of 08/3/2021 05:20 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume222,922 shs
Average Volume427,175 shs
Market Capitalization$497.63 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TCRR News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCR2 Therapeutics logo

About TCR2 Therapeutics

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies, including adult acute lymphoblastic leukemia, DLBCL, follicular lymphoma, and other non-hodgkin lymphomas that is in phase I/II clinical trial. It is also developing TC-510 for, GPC3, IL-15, and Allogenic for solid tumors, as well as DC70 for solid tumors and hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.27 out of 5 stars

Medical Sector

274th out of 1,309 stocks

Biological Products, Except Diagnostic Industry

38th out of 179 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

TCR2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions

Is TCR2 Therapeutics a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCR2 Therapeutics stock.
View analyst ratings for TCR2 Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than TCR2 Therapeutics?

Wall Street analysts have given TCR2 Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TCR2 Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is TCR2 Therapeutics' next earnings date?

TCR2 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for TCR2 Therapeutics

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) issued its earnings results on Thursday, May, 13th. The company reported ($0.58) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.55) by $0.03.
View TCR2 Therapeutics' earnings history

How has TCR2 Therapeutics' stock been impacted by Coronavirus (COVID-19)?

TCR2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TCRR shares have increased by 52.0% and is now trading at $13.04.
View which stocks have been most impacted by COVID-19

What price target have analysts set for TCRR?

9 equities research analysts have issued 12 month target prices for TCR2 Therapeutics' shares. Their forecasts range from $30.00 to $56.00. On average, they expect TCR2 Therapeutics' share price to reach $43.25 in the next twelve months. This suggests a possible upside of 231.7% from the stock's current price.
View analysts' price targets for TCR2 Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are TCR2 Therapeutics' key executives?

TCR2 Therapeutics' management team includes the following people:
  • Dr. Garry E. Menzel M.B.A., Ph.D., Pres, CEO & Director (Age 57, Pay $941.23k)
  • Mr. Mayur Amrat Somaiya, Chief Financial Officer (Age 48, Pay $592.88k)
  • Dr. Alfonso Quintás Cardama M.D., Chief Medical Officer (Age 50, Pay $678.58k)
  • Mr. Robert Hofmeister Ph.D., Chief Scientific Officer (Age 53)
  • Carl Mauch, Director of Investor Relations & Corp. Communications
  • Ms. Margaret Siegel, Head of Legal & Corp. Sec.
  • Dr. Angela Justice Ph.D., Chief People Officer (Age 49)
  • Mr. Gregg McConnell M.B.A., Head of Bus. Devel.
  • Mr. Stephen Turkowiak M.B.A., VP of Fin. & Treasurer

Who are some of TCR2 Therapeutics' key competitors?

What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

When did TCR2 Therapeutics IPO?

(TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are TCR2 Therapeutics' major shareholders?

TCR2 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (0.37%), New York State Common Retirement Fund (0.07%) and Alliancebernstein L.P. (0.07%). Company insiders that own TCR2 Therapeutics stock include Mayur Ian Somaiya, Morana Jovan-Embiricos, Neil W Gibson and Robert Hofmeister.
View institutional ownership trends for TCR2 Therapeutics

Which institutional investors are selling TCR2 Therapeutics stock?

TCRR stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc.. Company insiders that have sold TCR2 Therapeutics company stock in the last year include Mayur Ian Somaiya, and Robert Hofmeister.
View insider buying and selling activity for TCR2 Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying TCR2 Therapeutics stock?

TCRR stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., and New York State Common Retirement Fund.
View insider buying and selling activity for TCR2 Therapeutics
or or view top insider-buying stocks.

How do I buy shares of TCR2 Therapeutics?

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TCR2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $13.04.

How much money does TCR2 Therapeutics make?

TCR2 Therapeutics has a market capitalization of $497.63 million. The company earns $-67,120,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.

How many employees does TCR2 Therapeutics have?

TCR2 Therapeutics employs 131 workers across the globe.

What is TCR2 Therapeutics' official website?

The official website for TCR2 Therapeutics is

Where are TCR2 Therapeutics' headquarters?

TCR2 Therapeutics is headquartered at 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142.

How can I contact TCR2 Therapeutics?

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.